ROCO
4732
Market cap26mUSD
Oct 08, Last price
17.20TWD
1D
2.38%
1Q
-0.58%
Jan 2017
-6.16%
IPO
10.47%
Name
NatureWise Biotech & Medicals Corp
Chart & performance
P/E
—
P/S
4.70
EPS
—
Div yield, %
1.16%
Shrs. gr., 5y
-0.22%
Rev. gr., 5y
-10.45%
Revenues
177m
-21.20%
Net income
-118m
L
CFO
-113m
L+3,928.66%
Dividend
Aug 27, 20240.2 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
NatureWise Biotech & Medicals Corporation is a Taiwanese entity primarily engaged in the creation of pharmaceutical solutions. Its product lineup features LipoCol Forte, a capsule designed to address elevated cholesterol and triglyceride levels; PPL Taiwan green propolis; and NBM-BMX, an oral softgel formulation specifically developed for oncology treatment. The company was established in 2000 and maintains its headquarters in Taipei, Taiwan.
Key people
Wande Wu
Vice Chairman of the Board · since 2013
Xiaojing He
Deputy General Manager · since 2012
Xinhuang Lin
Deputy General Manager · since 2025
Jingjing Wu
Head of Finance and Accounting · since 2013
FL Hsu
Director
Minhua Hua
Director · since 2023
Zhongyang Huang
Chairman of the Board, Acting General Manager · since 2014
Junyao Lin
Director · since 2023
Director
An-Rong Lee
Independent Director · since 2020
Independent Director · since 2020
Caiwang Wang
Independent Director · since 2014
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||